Document is current
Any future updates will be listed below
-
Authors
Gogishvili, Miranda https://orcid.org/0000-0002-5143-6379
Melkadze, Tamar
Makharadze, Tamta
Giorgadze, Davit
Dvorkin, Mikhail
Penkov, Konstantin
Laktionov, Konstantin
Nemsadze, Gia
Nechaeva, Marina
Rozhkova, Irina
Kalinka, Ewa https://orcid.org/0000-0003-4791-8372
Gessner, Christian
Moreno-Jaime, Brizio
Passalacqua, Rodolfo
Li, Siyu
McGuire, Kristina
Kaul, Manika
Paccaly, Anne
Quek, Ruben G. W. https://orcid.org/0000-0001-9602-3239
Gao, Bo
Seebach, Frank
Weinreich, David M.
Yancopoulos, George D.
Lowy, Israel
Gullo, Giuseppe
Rietschel, Petra
-
Funding
Funding for this research was provided by:
Sanofi
Regeneron Pharmaceuticals
- License Information
-
More Information
Article History
Received: 23 May 2022
Accepted: 27 July 2022
First Online: 25 August 2022
Competing interests
: M.G., T. Melkadze, T. Makharadze, D.G., M.D., K.L., G.N., M.N., I.R. and B.M.-J. report no conflicts of interest. K.P. reports honoraria from AstraZeneca, Merck Sharp & Dohme, Nektar, Pfizer, Regeneron Pharmaceuticals and Roche and a consulting or advisory role with Nektar. E.K. reports honoraria from Merck Sharp & Dohme, Bristol Myers Squibb, Nektar, Pfizer, Roche, AstraZeneca, Amgen and Regeneron Pharmaceuticals. C.G. reports advisory board fees or honoraria from GlaxoSmithKline, Pfizer, AstraZeneca, Roche, Novartis, Bristol Myers Squibb, Merck Sharp & Dohme, Berlin-Chemie, Chiesi, Boehringer Ingelheim and Sanofi. R.P. reports advisory board or speaker roles for Astellas, Bristol Myers Squibb, Ipsen, Janssen, Merck Sharp & Dohme, Roche and Sanofi-Aventis and institutional funding for research projects from Amgen, AstraZeneca, Novartis and Pierre-Fabre. S.L., K.M., A.P., R.G.W.Q., B.G., F.S., D.M.W., G.D.Y., I.L., G.G. and P.R. are employees and shareholders of Regeneron Pharmaceuticals.
